ETFsBloomberg MSCI December 2026 Maturity EUR Corporate ESG Screened Index
iShares

iShares iBonds Dec 2026 Term € Corp UCITS ETF

IB26 XETRADistributingPhysical, sampledIreland
Last close · EUR
5.06EUR
0.00% · +€0.00
Published closes: 4 Nov 2026 - 5 Nov 2026
5 Nov 2026, close
IB26Base
Fund charges
Not publishedFee basis unverified
Fund size
Not published
Return 1Y
+2.0%
Sharpe 3Y
0.52
Volatility 1Y
0.8%annualised
Published holdings
44Fund holdings

Performance

Compare
  • IB26+2.0%
  • Price, EUR

Returns

Returns1M3M6MYTD1Y3Y5Y
IB26+0.2%+0.4%+1.2%+1.8%+2.0%+11.0%-
MSCI World-2.8%-0.6%+7.8%+14.0%+14.1%+65.6%+64.8%
Gap to MSCI World+3.0%+1.0%-6.6%-12.2%-12.1%-54.6%-

Risk and return

Sharpe ratio · 3Y
0.52
Below MSCI World · 1.24
Return p.a.
+3.5%
Volatility
1.4%
Max loss
-0.9%Jan 2024

Sharpe vs indices

MSCI World
1.24
S&P 500
1.21
STOXX Europe 600
1.04
MSCI Emerging Markets IMI
0.93
IB26
0.52
CAC 40
0.37
Method

Weekly EUR returns from adjusted closes. Sharpe is the annualised excess return over the euro overnight rate (Xtrackers II EUR Overnight Rate Swap UCITS ETF 1C) divided by its volatility. Max loss uses daily closes.

Top holdings

Top 10 published holdings
42.9%
Published holdings
44
As of
Fund holdings

Partial · lower bound · Reported coverage: 57.7% · Unknown: 42.3%

  1. 1GERMANY (FEDERAL REPUBLIC OF) RegS18.61%
  2. 2FRANCE (REPUBLIC OF) RegS18.52%
  3. 3SKANDINAVISKA ENSKILDA BANKEN AB MTN RegS1.03%
  4. 4TAKEDA PHARMACEUTICAL COMPANY LIMI RegS0.83%
  5. 5APPLE INC0.77%
  6. 6INTESA SANPAOLO SPA MTN RegS0.71%
  7. 7COMMERZBANK AG MTN RegS0.66%
  8. 8COMPAGNIE DE SAINT GOBAIN SA MTN RegS0.61%
  9. 9OMV AG MTN RegS0.60%
  10. 10CAIXABANK SA RegS0.59%

Countries

Classified 96.6%
Largest
47.4%France
Top 3
88.0%
Effective number
2.71 / HHI

Market cap

Weight vs holdings

42.9%of the fund is in the 10 largest published holdings

Partial · lower bound · Reported coverage: 57.7% · Unknown: 42.3%

Size split

Not published

Compare ETFs in Copio.

ETF comparison in the Copio app, showing costs and returns with illustrative data.

Factual research, without a suitability score or investment recommendation. Past relationships can change.